The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among Persons Living with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy.
Antiretroviral Therapy, Highly Active
/ methods
CD4-Positive T-Lymphocytes
/ drug effects
Cross-Over Studies
Double-Blind Method
Female
Gastrointestinal Microbiome
/ drug effects
HIV
/ drug effects
HIV Infections
/ drug therapy
Humans
Immunity, Mucosal
/ drug effects
Inflammation
/ drug therapy
Interleukin-6
/ metabolism
Lactoferrin
/ therapeutic use
Lymphocyte Activation
/ drug effects
Male
Middle Aged
Recombinant Fusion Proteins
/ therapeutic use
Viral Load
/ drug effects
HIV
immune activation
inflammation
lactoferrin
microbiome
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
24 05 2019
24 05 2019
Historique:
received:
10
10
2018
accepted:
31
01
2019
pubmed:
6
2
2019
medline:
25
2
2020
entrez:
6
2
2019
Statut:
ppublish
Résumé
Lactoferrin modulates mucosal immunity and targets mechanisms contributing to inflammation during human immunodeficiency virus disease. A randomized placebo-controlled crossover clinical trial of recombinant human (rh) lactoferrin was conducted among 54 human immunodeficiency virus-infected participants with viral suppression. Outcomes were tolerability, inflammatory, and immunologic measures, and the intestinal microbiome. The median age was 51 years, and the median CD4+ cell count was 651/µL. Adherence and adverse events did not differ between rh-lactoferrin and placebo. There was no significant effect on plasma interleukin-6 or D-dimer levels, nor on monocyte/T-cell activation, mucosal integrity, or intestinal microbiota diversity. Oral administration of rh-lactoferrin was safe but did not reduce inflammation and immune activation. Clinical Trials Registration: NCT01830595.
Identifiants
pubmed: 30721997
pii: 5306488
doi: 10.1093/infdis/jiz042
pmc: PMC6784498
doi:
Substances chimiques
Interleukin-6
0
Recombinant Fusion Proteins
0
Lactoferrin
EC 3.4.21.-
Banques de données
ClinicalTrials.gov
['NCT01830595']
Types de publication
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1963-1968Subventions
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
PLoS Med. 2008 Oct 21;5(10):e203
pubmed: 18942885
Cell Immunol. 2002 Dec;220(2):83-95
pubmed: 12657243
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
Biometals. 2010 Jun;23(3):411-7
pubmed: 20407805
J Gastroenterol Hepatol. 2002 Dec;17(12):1291-8
pubmed: 12423274
PLoS One. 2014 Apr 11;9(4):e95061
pubmed: 24728071
Pediatr Res. 1996 Aug;40(2):257-62
pubmed: 8827774
PLoS One. 2016 May 12;11(5):e0155100
pubmed: 27171281
J Crohns Colitis. 2017 Sep 1;11(9):1101-1112
pubmed: 28472424
Crit Care Med. 2013 Mar;41(3):706-16
pubmed: 23425819
J Infect Dis. 2010 Jun 15;201(12):1788-95
pubmed: 20446848
Biochem Cell Biol. 2012 Jun;90(3):269-78
pubmed: 22300429
Yakugaku Zasshi. 2008 Sep;128(9):1363-8
pubmed: 18758152
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131